Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Lenvatinib for Unresectable HCC
NCT04490694Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04490694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490694.